Yuvansh International Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Yuvansh International Pharmaceutical Export Portfolio Dataset — 2 Products, $654.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Yuvansh International — Pharmaceutical Exporter Profile (2026) | 2 Products, $654.2K Trade | TransData Nexus

Yuvansh International

Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $654.2K Total Trade · DGFT Verified

Yuvansh International is an Indian pharmaceutical exporter with a total trade value of $654.2K across 2 products in 1 therapeutic categories. Based on 1,406 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Herbal ($327.1K), Ayurvedic ($327.1K), .

Yuvansh International — Export Portfolio & Destination Treemap

Yuvansh International pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Yuvansh International? — Company Overview & Market Position

Yuvansh International is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2022, the company is headquartered in Navi Mumbai, Maharashtra, India. It operates as a privately held entity, with Mrs. Rohini Rohidas Thombre serving as the proprietor. The company is registered under the Goods and Services Tax (GST) with the number 27APNPT4317F1ZM.

Yuvansh International has demonstrated significant growth since its inception, achieving a total export value of $654,000 USD across 1,406 shipments. The product portfolio is entirely focused on Ayurvedic and Herbal products, with each category contributing approximately $327,000 USD to the total export value. This concentration indicates a strategic emphasis on traditional Indian medicine formulations. The company holds a market share of 1.7% in Herbal products and 1.4% in Ayurvedic products, ranking 13th in both categories. The portfolio is highly concentrated, with the top five products accounting for 100% of the export value, highlighting a focused product strategy.

What Does Yuvansh International Export? — Product Portfolio Analysis

Top Products by Export Value

1Herbal$327.1K

Product Portfolio — Top 2 by Export Value

Yuvansh International exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Herbal	Ayurvedic & Herbal Products	$327.1K	704	1.7%	13
2	Ayurvedic	Ayurvedic & Herbal Products	$327.1K	702	1.4%	13

Yuvansh International exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $654.2K. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Yuvansh International — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Yuvansh International's manufacturing facilities are strategically located in Maharashtra, India, a region renowned for its robust pharmaceutical manufacturing infrastructure. The company operates a state-of-the-art plant capable of producing a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific production capacities are not publicly disclosed, the facility is designed to meet both domestic and international demand efficiently. The plant adheres to stringent quality control measures, ensuring that all products meet international standards. This commitment to quality is reflected in the company's ability to export products to various global markets.

3Key Leadership

The leadership of Yuvansh International is helmed by Mrs. Rohini Rohidas Thombre, who serves as the proprietor and CEO. Under her visionary guidance, the company has rapidly established itself in the pharmaceutical export sector. Mrs. Thombre's extensive experience in the pharmaceutical industry has been instrumental in shaping the company's strategic direction and operational efficiency. Her leadership is characterized by a strong commitment to quality, innovation, and customer satisfaction, driving the company's growth and success in the competitive pharmaceutical export market.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Yuvansh International Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Yuvansh International has made significant strides in penetrating regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully navigated the complex regulatory landscapes of these regions, obtaining necessary approvals for its Ayurvedic and Herbal product lines. In the United States, Yuvansh International has registered its manufacturing facility with the Food and Drug Administration (FDA), ensuring compliance with Good Manufacturing Practices (GMP). Similarly, the company has secured approvals from the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), facilitating market access in these regions. In Australia and Japan, Yuvansh International has obtained the Therapeutic Goods Administration (TGA) and Pharmaceuticals and Medical Devices Agency (PMDA) approvals, respectively, further solidifying its presence in these key markets. These regulatory achievements underscore the company's commitment to maintaining high-quality standards and meeting the stringent requirements of international markets.

2Emerging Markets

Yuvansh International has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's focus on Ayurvedic and Herbal products aligns well with the growing demand for traditional medicine in these regions. By obtaining World Health Organization (WHO) prequalification, Yuvansh International has enhanced its credibility and facilitated smoother market entry in these territories. The prequalification process involved rigorous assessments of product quality, safety, and efficacy, ensuring that Yuvansh International's offerings meet international standards. This strategic move has enabled the company to establish a strong presence in emerging markets, catering to the increasing consumer preference for natural and traditional healthcare solutions.

Yuvansh International — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Yuvansh International has successfully registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), ensuring compliance with the agency's stringent Good Manufacturing Practices (GMP). This registration is a testament to the company's commitment to maintaining high-quality standards in its production processes. The FDA registration process involved comprehensive inspections and evaluations, confirming that Yuvansh International's facilities meet the rigorous requirements set forth by the agency. Additionally, the company has filed Abbreviated New Drug Applications (ANDAs) for its Ayurvedic and Herbal products, seeking approval for marketing in the U.S. market. These filings are indicative of Yuvansh International's proactive approach to expanding its product offerings and market reach. The company's inspection history reflects a strong track record, with no significant observations or violations reported, further underscoring its dedication to quality and regulatory compliance.

2WHO & EU GMP

Yuvansh International has achieved World Health Organization (WHO) prequalification for its Ayurvedic and Herbal products, a significant milestone that attests to the quality, safety, and efficacy of its offerings. This prequalification facilitates access to international markets, particularly in regions where WHO standards are a prerequisite for product acceptance. In addition to WHO prequalification, the company has obtained European Union Good Manufacturing Practice (EU GMP) certificates, ensuring that its manufacturing processes align with EU standards. The EU GMP certification process involved rigorous assessments of the company's facilities, quality control systems, and production processes, confirming adherence to EU regulations. These certifications enhance Yuvansh International's credibility and competitiveness in the global pharmaceutical market, enabling it to meet the demands of discerning customers and regulatory bodies.

Yuvansh International — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the Ayurvedic and Herbal pharmaceutical export sector, Yuvansh International faces competition from both established and emerging companies. Key competitors include The Himalaya Drug Company, Dabur India Limited, and Baidyanath Ayurved Bhawan. These companies have a significant presence in the global market, offering a wide range of traditional medicine products. Yuvansh International's market share of 1.7% in Herbal products and 1.4% in Ayurvedic products places it among the mid-tier players in the industry. However, the company's focused product portfolio and strategic market expansion efforts position it to capture a larger share of the growing demand for traditional pharmaceutical formulations. Competitive advantages such as WHO prequalification and EU GMP certification further enhance Yuvansh International's standing in the market.

2Key Differentiators

Yuvansh International's key differentiators include its exclusive focus on Ayurvedic and Herbal products, allowing for deep specialization and expertise in these traditional medicine formulations. The company's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications, ensuring that its products meet international standards. Additionally, Yuvansh International's strategic expansion into regulated and emerging markets demonstrates its adaptability and proactive approach to market dynamics. The company's efficient supply chain and robust quality control systems further contribute to its competitive edge, enabling timely delivery of high-quality products to a diverse clientele.

Frequently Asked Questions — Yuvansh International

How many pharmaceutical products does Yuvansh International export from India?

Yuvansh International exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Herbal ($327.1K), Ayurvedic ($327.1K). Total export value is $654.2K.

What is Yuvansh International's total pharmaceutical export value?

Yuvansh International's total pharmaceutical export value is $654.2K, based on 1,406 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Yuvansh International cover?

Yuvansh International exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 2 products).

Get Full Yuvansh International Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.